Selumetinib

Drug Profile

Selumetinib

Alternative Names: ARRY-142886; ARRY-886; AZD 142886; AZD-6244; AZD-6244 hydrogen sulfate; AZD6244 Hyd-Sulfate; AZD6244 hydrogen sulphate; NSC-748727; Selumetinib hydrogen sulfate

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Array BioPharma
  • Developer Array BioPharma; AstraZeneca; Cancer Research UK; Cincinnati Children's Hospital Medical Center; Merck & Co; National Cancer Centre (Singapore); National Cancer Institute (USA); Netherlands Cancer Institute; University Health Network; University of Cambridge; University of Liverpool
  • Class Antineoplastics; Benzimidazoles; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Uveal melanoma; Thyroid cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Thyroid cancer
  • Phase II Biliary cancer; Colorectal cancer; Gastrointestinal stromal tumours; Glioma; Histiocytosis; Neurofibromatoses; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Solid tumours; Uveal melanoma
  • Phase I/II Astrocytoma
  • Preclinical Pancreatic cancer
  • Discontinued Acute myeloid leukaemia; Hepatocellular carcinoma; Malignant melanoma; Multiple myeloma

Most Recent Events

  • 21 Aug 2017 AstraZeneca initiates an intermediate access protocol for Neurofibromatoses in USA (NCT03259633)
  • 04 Aug 2017 AstaZeneca initiates enrolment in a phase I trial for Solid tumours (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (PO) (NCT03162627)
  • 01 Aug 2017 Merck and AstraZeneca enter into an agreement to co-develop and co-commercialise selumetinib as monotherapy and combination therapy for cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top